Is it safe to take Naltrexone (50mg daily) with Tylenol 3 (acetaminophen and codeine) and morphine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Naltrexone and Opioid Co-Administration: Critical Safety Concern

Do not take naltrexone 50mg daily with Tylenol 3 (codeine) or morphine—naltrexone will block the analgesic effects of these opioids and may precipitate acute opioid withdrawal if you are opioid-dependent. 1

Mechanism of Contraindication

  • Naltrexone is a mu-opioid receptor antagonist that directly blocks the therapeutic effects of opioid agonists like morphine and codeine 1, 2
  • The antagonism occurs at the same receptor sites where morphine and codeine produce analgesia, rendering these pain medications ineffective 2, 3
  • In opioid-dependent patients, naltrexone can precipitate acute withdrawal symptoms including agitation, muscle aches, sweating, nausea, and potentially severe cardiovascular effects 1, 4

Clinical Guidelines on This Combination

The American Gastroenterological Association explicitly states that naltrexone-containing medications should not be used in patients requiring short-term or long-term opiate therapy because naltrexone could reduce analgesic efficacy or precipitate withdrawal 1

  • Naltrexone must be discontinued before any procedures requiring opioid analgesia (such as endoscopies using fentanyl) 1
  • The National Comprehensive Cancer Network warns against using mixed agonist-antagonist combinations with pure opioid agonists, as this can precipitate withdrawal in opioid-dependent patients 5

Special Formulation Exception

  • There exists a specific extended-release morphine/naltrexone combination product (EMBEDA) designed for chronic pain management where naltrexone is sequestered within the pellet core 2, 4
  • When taken intact as directed, this formulation releases minimal naltrexone (therapeutic naltrexone concentrations remain undetectable in most patients), allowing morphine to provide analgesia 2, 4
  • The sequestered naltrexone only becomes bioavailable if the capsule is crushed or tampered with, serving as an abuse-deterrent mechanism 2, 4
  • This is fundamentally different from taking standard naltrexone 50mg daily tablets alongside separate opioid medications 2

What Happens If Combined

  • Complete or near-complete blockade of opioid analgesia—your pain will not be controlled despite taking morphine or codeine 1, 2
  • Risk of precipitated withdrawal if you have been taking opioids regularly and have developed physical dependence 1, 4
  • Wasted medication costs and continued suffering from uncontrolled pain 1

Alternative Pain Management Strategies

If you require both opioid antagonist therapy (for alcohol use disorder or opioid use disorder maintenance) and pain control:

  • Naltrexone must be discontinued at least 7-10 days before initiating opioid therapy to allow receptor availability 1
  • Consider non-opioid analgesics: acetaminophen alone (without codeine), NSAIDs, gabapentinoids, or topical agents depending on pain etiology 1
  • For severe pain requiring opioids, work with your prescriber to temporarily hold naltrexone therapy 1
  • Regional anesthesia or interventional pain procedures may provide analgesia without systemic opioids 1

Critical Timing Considerations

  • Naltrexone has a duration of action of 24-72 hours depending on dose 1
  • After stopping naltrexone 50mg daily, wait at least 7-10 days before expecting full opioid analgesic response 1
  • Do not attempt to "override" naltrexone blockade by taking higher opioid doses—this increases overdose risk without improving analgesia 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Evidence from basic research for opioid combinations.

Expert opinion on drug discovery, 2012

Research

Morphine/naltrexone.

CNS drugs, 2010

Guideline

Opioid Cross-Reactivity and Safety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.